The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 23, 2007

Filed:

Nov. 21, 2003
Applicants:

Rima Kaddurah-daouk, Belmont, MA (US);

Ghaleb Daouk, Belmont, MA (US);

M. Flint Beal, New York, NY (US);

Inventors:

Rima Kaddurah-Daouk, Belmont, MA (US);

Ghaleb Daouk, Belmont, MA (US);

M. Flint Beal, New York, NY (US);

Assignees:

Avicena Group, Inc., Palo Alto, CA (US);

The General Hospital Corp., Boston, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A01N 37/52 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention relates to the use of creatine compounds including creatine, creatine phosphate or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compounds can be used as therapeutically effective agents against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer's disease, Parkinson's disease, stroke, Huntington's disease, amyotropic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination and demyelination disorders, and mitochondrial diseases. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) bisubstrate inhibitors of creatine kinase comprising covalently linked structural analogs of adenosine triphosphate (ATP) and creatine; (3) creatine analogs which can act as reversible or irreversible inhibitors of creatine kinase; and (4) N-phosphorocreatine analogs bearing non-transferable moieties which mimic the N-phosphoryl group.


Find Patent Forward Citations

Loading…